Terminology Service for NFDI4Health
All terms in BAO
| Label | Id | Description |
|---|---|---|
| coupled cluster method | BAO_0002324 | |
| sulfhemoglobinemia | DOID_12451 | |
| blood protein disease | DOID_620 | |
| pulpitis | DOID_11121 | |
| pancytopenia | DOID_12450 | |
| hypermobility syndrome | DOID_13781 | |
| neuron development | GO_0048666 | [The process whose specific outcome is the progression of a neuron over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.] |
| 293T/17 cell | CLO_0001235 | |
| HEK293 | CLO_0001230 | |
| Henoch-Schoenlein purpura | DOID_11123 | |
| hypersensitivity vasculitis | DOID_9809 | |
| R18 peptide | BAO_0001004 | [The peptide sequence, PHCVPRDLSWLDLEANMCLP, named R18, was identified as an unphosphorylated peptide that binds to 14-3-3 proteins with high affinity (Kd=80 nM). It has been shown to bind to the same amphipathic groove on the surface of 14-3-3 as phosphorylated peptides. R18 can inhibit the formation of the 14-3-3-Raf-1 complex, reduce Raf-1 dependent transcriptional activity in cells and block the activation of ExoS by 14-3-3. It binds to all the 14-3-3 isoforms with equal affinities. This peptide is useful for competitive inhibition experiments.] |
| hypervitaminosis D | DOID_9971 | |
| pyrimidine-4,6-dicarboxylic acid | BAO_0001003 | [pyrimidine-4,6-dicarboxylic acid, bis-(4-fluoro-3-methyl-benzylamide) Degrades collagen type I.] |
| completely randomized design | BAO_0002337 | |
| obesity | DOID_9970 | |
| Pyr-RTKR-AMC | BAO_0001002 | |
| fractional factorial design | BAO_0002338 | |
| prostaglandin E2 | BAO_0001001 | |
| full factorial design | BAO_0002339 |